In advance of the long-awaited Dobbs decision, which repealed Roe v. Wade, Reed Smith’s Life Sciences Health Industry Group has started analyzing – and advising on – the legal impact this decision will have on health care providers, pharmacies, manufacturers, insurers, distributors, and other industry entities. While there are currently more questions than answers, such a reversal will have profound implications on a wide range of issues, including private rights of action, physician or pharmacist practice acts, licensing considerations, coverage by payors, and possible criminal or civil implications associated with dispensing certain medications or providing health care services, particularly in some states.
Our team is also examining how this decision at the federal level will trigger changes to many state laws, which will require clients with national or multi-state operations to comply with numerous conflicting laws and regulations.
To help understand these issues, Reed Smith has formed a Reproductive Health Working Group - consisting of regulatory, investigations, and litigation lawyers, along with health policy analysts - all of whom focus exclusively on the health care and life sciences sector, so that we can help clients anticipate potential business issues or disruptions, government enforcement, billing and reimbursement challenges, and even civil or criminal litigation.
To connect directly with this team, email our Reproductive Health Working Group.
For additional insight on this developing area, please view our resources below. For news on this and other health care and life sciences developments, please subscribe to our Health Industry Washington Watch blog. Subscribe to our mailing lists to receive client alerts, webinar and event invitations and other thought leadership.
